Recorded source agreement and disagreement

Compared medicine fields

1,681

Agree

1,282

Differ

0

Not comparable

12

Insufficient context

387

Fields represented

5

bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

• Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
• The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
• Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
• Only the recorded fields and source documents in this snapshot are compared.
• A source count is the number of retained source records in the row, not a count of independent experiments.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Showing 221–230 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

1. Projected row 221

   Medicine slug

   bupropion

   Compared field

   halfLife

   Comparison state

   agree

   Reason codes

   • COMPATIBLE_VALUES_OVERLAP

   Documents examined

   251

   Source count

   120

   Agreement rate

   1

   Recorded readings

   1. 29 hours

      Numeric value

      29

      Unit

      hours

      Source records

      120

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 120 source records

      1. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:d5469d64-5e74-4b7a-b4cd-551665f6adaa (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      2. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:459bd1c9-d7a5-8bc9-e063-6394a90a8ecd (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      3. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:722650d8-5ee4-48ba-9827-7c86b1283522 (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         In addition, in patients with severe hepatic cirrhosis, the bupropion Cmax and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      4. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:b4a1d3b8-afcf-47e3-96d3-469d8f408a31 (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      5. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:c280efb9-b284-6a69-e053-2995a90a3035 (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         In addition, in patients with severe hepatic cirrhosis, the bupropion Cmax and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      6. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:47ceb7e1-b2f7-47f8-8b6a-85eea36606b8 (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3 fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      7. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:9d08b4ae-077d-4cd8-9ca4-8d5cd63f400b (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      8. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:45789ff4-af5d-96b0-e063-6394a90a0644 (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      9. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:487271f1-c956-086a-e063-6394a90a2dc7 (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      10. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:6902b252-dc69-4b3c-bad2-b6667a5f6d84 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      11. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:039d4368-c764-463a-b0cd-1cac702b8fb2 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      12. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:a5417808-f767-48fc-9f5d-c1aeee4e57c3 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      13. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:16a788ff-8bd5-4f70-a3fd-a89db019e435 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      14. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:98d5977f-9b32-46db-bd36-a2c4d1b0710a (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs 19 hours in healthy subjects).

      15. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:0cd6e0e2-6b2c-4e0d-b5b2-ebfe0d5e31c4 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      16. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:004d8121-59d4-46c4-acb8-b2dd097bf556 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      17. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:ae3bcdf7-d7f3-4f07-8113-af08af20a0d4 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      18. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:e4e38abf-ef67-405b-af2d-3d8e4533654d (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      19. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:d4272e3f-78ee-4d80-b911-e840fb14acbe (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in patients with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      20. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:ef8ef9ba-ab2a-4af9-ac11-12dd1b603a4a (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      21. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:5dec4414-5595-46c9-ada9-3fbe98152040 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      22. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:8dab6d17-bf41-4a28-90db-b66959c0e143 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      23. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:3ec04240-baef-44d7-8d73-a181171eec43 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion Cmax and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      24. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:cc344f7c-0eb3-4e63-a09e-b682acca2bb5 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      25. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:f53704b2-3d3c-47e8-9fd6-a0f5240c0593 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      26. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:7c46d95a-26f6-4364-8197-9e564e3405f2 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      27. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:15ad0c66-1829-59c3-e063-6394a90a4384 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      28. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:e57451fd-aba5-47d6-9892-ffe2a6021b6f (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      29. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:64be3113-837a-48f3-9f9e-400529c9ee94 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      30. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:9d5360f5-f747-4baf-8e6c-ddca1a9c871a (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      31. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:fddc9630-2f9a-4104-888f-3714587d4fe7 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      32. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:d087222e-c5e9-4c48-b27f-e2e2944379c8 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      33. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:a435da9d-f6e8-4ddc-897d-8cd2bf777b21 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      34. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:ed27c415-9f29-4789-9da4-4a14aaba95bd (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion Cmax and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      35. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:4ddf6ba2-c020-7912-e063-6394a90a7964 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      36. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:af5b1cc8-f078-4a7b-b64a-4cb2de1e5721 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      37. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:5ccec958-998d-43a1-86fb-eb2b5e697b77 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      38. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:458c8a67-4995-c772-e063-6394a90a1f8d (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      39. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:eee88553-acff-4bdd-acd1-f39bcb6fcdca (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      40. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:d6efb695-c439-48d7-a155-5c661a5049af (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      41. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:0ac739de-ad59-4882-810e-f52db22ac96f (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      42. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:069e6828-e599-4614-9645-9cf1382ac93e (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      43. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:75b1e027-4c5d-46e5-98ee-033e67bd411c (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      44. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:c71f18b7-36a3-4489-96b4-e8fbec4f73a1 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      45. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:512b0ed3-db7d-b273-e063-6394a90a25cc (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      46. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:cefaaa17-f79a-4ba6-8f97-a59f60e07b75 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      47. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:56df4e22-81ca-48a4-a8e2-038448417355 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      48. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:f2b30440-0e07-2670-e053-2995a90afa28 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      49. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:34686e9d-c106-4276-8b47-7460cca8860e (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      50. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:a613cfd3-1aa1-49c5-b742-b105c97d73f1 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      51. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:29a6c6e3-f30f-6541-e063-6394a90ae11d (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      52. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:57a9f4d3-0c41-4978-b81e-cf3059bc8c42 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      53. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:0abd64f7-5142-48f6-a487-3f5bdc3400de (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion Cmax and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      54. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:62d0dcb5-c70b-4884-9755-740f62a8b31a (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      55. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:2af578d8-a7f8-4da3-b126-390a0e950fad (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion Cmax and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      56. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:4a2be6af-e256-4fa9-bfa9-5300d52cdaf4 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      57. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:80f4a4ef-8190-458d-af2e-5daaf32abc01 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      58. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:178c7129-a752-4ad9-ac82-4473e23bbacc (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      59. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:f8af7829-8b61-6785-e053-6294a90af052 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      60. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:2ccbf988-64b6-3a60-e063-6394a90ababa (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      61. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:16ffe2ac-4f71-4843-99df-611f53c2f3cd (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion Cmax and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      62. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:f79d1422-a9b6-41c2-a46d-22886605f94d (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      63. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:740534d3-59b5-4938-8e38-16275a14438c (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      64. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:aa3d3e5b-74a3-47f6-b9aa-d6e248e950e5 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      65. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:d1d0872c-5b11-4e13-a401-b122348e0fa7 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      66. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:9e2d9c1e-a1de-491d-8f64-34ae60419611 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      67. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:637e89e5-8f6e-4392-8045-a778cb9ed138 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      68. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:4956af38-182a-4015-a945-67e40bd38772 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      69. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:42e228a2-25b3-44a6-8da7-6616ca44ac7f (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      70. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:e4f4d3fa-ddf6-4125-8486-8157efc095c1 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      71. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:a7553281-be90-47e3-8d2b-b027f6d18d3a (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      72. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:bf5e933c-8a84-4dd7-a05d-6c4a82b6c965 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      73. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:53c192ca-ac51-cb87-e063-6394a90a6c08 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      74. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:9aa3753f-1a0e-4faa-995f-67e29b320737 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      75. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:080853c0-fcab-4645-9ddc-4946e895ac5f (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      76. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:e47df78d-5e9b-485d-8d92-0e00602f7a31 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      77. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:a0fdfc21-165a-43fa-9b3c-e48f3b892250 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      78. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:c2cf79d7-1aba-4391-980b-5e218781f7c6 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      79. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:ec9cbb38-1582-492f-a526-4b3675c55b14 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      80. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:5d40e301-7e06-4ecd-b7c6-3d7ac6a134d2 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      81. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:8d937ca3-3351-40f1-8192-348ba0c68162 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3 fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      82. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:82bcdd72-9146-4c8d-a8aa-f92015864605 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      83. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:02275c51-6b3e-434a-bdb5-99135e73f1a4 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      84. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:4cc3327b-92c5-4667-ae16-3e95eafcf4d8 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      85. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:96e78f74-fad0-4ae1-9e68-55e4c6ab2d60 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      86. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:8a0781c0-e7d5-498e-b7d3-d6bd457f175f (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      87. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:8ae81b03-b447-4a3f-8ed9-ebf75ee52b49 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      88. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:42201f4a-8856-4499-8bc3-d18612b1ec34 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      89. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:5e568bb5-542a-4395-a21e-dc64281d694e (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      90. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:aeb506f8-97c2-409a-aac9-5a73c840e8f3 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      91. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:0e8b2109-8516-2d92-e063-6394a90a5d16 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      92. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:06d4d890-11ed-4f31-8778-c73432e3ea69 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      93. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:3d826804-6427-aae1-e063-6394a90a6593 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      94. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:eb25adb1-9841-42ce-aa22-718fb0fba5dd (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      95. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:8499470a-8d01-4348-b67b-8f49728031cb (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      96. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:b2e6c30f-a33c-4854-ab19-bc9f65880374 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      97. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:c60855ca-4fa0-4004-ad19-4abb61100c43 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      98. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:30c370c2-f2b7-4335-ba55-e8c8f4059092 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      99. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:136f29fa-a859-4efb-8365-1382716d6f8f (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      100. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:1724f474-d6ab-46af-940f-7f874d4ff7fc (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      101. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:15c4e95a-d203-4caf-b6c7-44792355cb76 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      102. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:05f82eca-cc87-4580-acd7-e6491c651881 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      103. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:6494d2d9-0ce4-4126-b1c7-49684395942b (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In addition, in patients with severe hepatic cirrhosis, the bupropion Cmax and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      104. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:d9eb0939-63c1-48c4-a444-a899d7924d06 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      105. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:f1703bfd-be36-4fde-8e67-df0fb5d93369 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      106. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:df923448-4f81-47af-8e55-f7359746b05f (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      107. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:1af14d2e-c64d-44b7-a402-8869e8e30661 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      108. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:82872e51-3349-40fe-8ea3-496751955fed (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      109. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:a225dbbb-86f0-4547-a1c8-68eb64cd6892 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      110. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:dfd5f264-d4fd-4441-88b1-48086c7c0616 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      111. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:8d9779e7-300e-4720-8ba5-2272b2506cd9 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      112. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:77b78d35-40f5-4713-8468-aa09a6c2925d (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      113. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:a18b5460-fcbb-42dd-8b87-197d11a08928 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      114. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:2aabf040-16a6-b772-e063-6294a90afd70 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In addition, in patients with severe hepatic cirrhosis, the bupropion Cmax and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      115. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:2f9c5162-a6c5-e362-e063-6294a90a198d (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      116. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:80b01182-dc94-4990-8ebb-55c306d7e536 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs 19 hours in healthy subjects).

      117. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:03b1b0a9-0aa2-4039-acce-68ca54abaae4 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      118. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:eb946d81-b4f4-42e9-aa7a-31d76d15629c (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      119. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:a1e768fd-c28f-4b49-822d-ccc315b4099c (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

      120. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:bcbef1b4-a135-4231-bc65-7d0b335260e8 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In addition, in patients with severe hepatic cirrhosis, the bupropion C max and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in subjects with severe hepatic cirrhosis vs. 19 hours in healthy subjects).

2. Projected row 222

   Medicine slug

   bupropion

   Compared field

   tMax

   Comparison state

   insufficient_context

   Reason codes

   • STRUCTURED_CONTEXT_MISSING

   Documents examined

   251

   Source count

   251

   Agreement rate

   0.525896

   Recorded readings

   1. 3 hours

      Numeric value

      3

      Unit

      hours

      Source records

      132

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 132 source records

      1. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:507112bd-a082-e85a-e063-6294a90ab2ac (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      2. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:13560bf8-eb25-44f0-968e-db70d51219af (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      3. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:144379e1-93b7-41c1-bc3a-7bdec5afa309 (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      4. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:1094ff8e-f5a5-4a72-8bf9-25e68f5c964a (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      5. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:86530199-999b-9f92-b1bc-b8515ec829f3 (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      6. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:eeb3fed1-2202-09fc-e053-2995a90a9f63 (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      7. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:9196568e-aec8-4d56-993e-4cbb78d4a3a6 (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      8. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:3b73d56e-e558-49de-8126-d7ec9b67a086 (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      9. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:bcb4ef83-f272-4090-8547-9aaf4ab63667 (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      10. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:d86e26e0-6e10-4d59-8cc8-94b551774b86 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride and are approximately 10 times the peak level of the parent drug at steady state.

      11. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:b127d3fc-be5e-4c12-8026-205766bf8e7f (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      12. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:ef0bb8f2-7710-4236-8b47-57b74c8bca3e (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      13. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:850ac56a-ba50-4e61-b1ee-805e17735b5c (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release (SR) tablets, peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      14. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:21be6b3b-add3-43e7-af93-30350aefc89e (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      15. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:cec41945-8d64-4793-8784-4c2b8ec37b0f (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      16. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:b47c5515-a438-40bc-b8ad-26a6cf9676b7 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      17. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:161637d2-bc9d-4a2b-ad1f-6cc39ffd69ce (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      18. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:093c4a61-02d9-4b55-b612-569aa25d3f2a (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      19. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:f2b3939b-a410-6354-e053-2995a90ababb (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR) peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      20. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:0574b84d-075f-410f-a8eb-86901e307ea2 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR) peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      21. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:78ef709a-f835-4b03-92dd-16a4c82af0c1 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      22. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:d4272e3f-78ee-4d80-b911-e840fb14acbe (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption: Following oral administration of bupropion hydrochloride extended-release tablets (SR) to healthy volunteers, peak plasma concentrations of bupropion are achieved within 3 hours.

      23. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:500fc18d-93b4-47d5-a3f7-3f68822d83e8 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR) peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      24. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:634bc654-be95-4fea-b308-eed53269a112 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR) peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      25. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:744f7394-aac9-4864-9436-e5b0b35a6148 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      26. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:0aa86bd6-b37b-45f7-a837-b067e41184e9 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      27. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:990587bd-4c7d-4a36-8a38-3104648ab3a2 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      28. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:ab6cd2ea-507c-35e5-e053-2a95a90ac5cb (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release (SR) tablets, peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      29. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:67b6bcf8-0e7c-4e74-ad72-54f1bd6e65ad (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release (SR) tablets, peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      30. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:434aacf8-87f1-44fc-a66b-92ae0022de0e (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      31. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:362504fd-2f0a-c097-e063-6394a90ac0fc (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      32. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:a72db723-df4b-4bf4-9bdc-05ae82058696 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      33. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:2bb61b34-653a-43b4-9682-705d5b82d18e (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets, (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      34. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:eabb54b7-164c-4de8-b91a-f2e65637b5fc (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      35. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:8f86f677-2ebd-43c4-b2dd-2e07d4d54147 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      36. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:aef84c3a-68e2-e9d9-e053-2995a90a4ab8 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      37. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:87dac2ee-732c-465b-8ffe-e5aeba421425 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      38. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:9d2c209b-248e-4e26-9cde-fe0abe4428c1 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      39. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:dfb45438-1116-48f2-9bfe-776ebbf1e119 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      40. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:994229b0-e190-49e3-83ce-6a2063f7335a (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      41. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:81d251aa-a8e8-493e-94ed-12f6fb8902e6 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      42. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:33210109-2ddb-4b0f-a45e-988e493ca628 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      43. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:f58ce435-b124-4519-98d8-de2d00f61b01 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      44. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:5c111cf0-0199-4a4d-8138-81579af4c14d (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      45. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:30c5b97c-b19d-4d27-bb1a-ab19b7dfccaa (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      46. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:0b33fb1f-a7f0-4ab7-a882-eca2d2c77afa (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      47. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:9490d611-b679-45c7-e053-2a95a90afb87 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      48. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:fa5fa0d8-d27f-44e1-8868-dfa7206524e2 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      49. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:909204fc-ff55-43d9-b9ee-e607ef60965e (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of Bupropion Hydrochloride Extended-release (SR) tablets, peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      50. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:339c7157-1c65-40d1-bbcc-c10348d908d3 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      51. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:73167de9-948d-465c-88c0-c7743a79e7f5 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      52. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:ec8c699f-a8de-4e5a-a223-8de3f5dfe20d (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      53. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:a724b3b6-f60e-4b88-8603-8141a32075da (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      54. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:1bd2ed35-35c5-464f-bf51-9dd4b42ee59a (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      55. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:a591e33a-52f0-41c8-a00b-4a1afcc3dc4c (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      56. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:c0445fea-108f-4e00-a2ae-ebbdf2719947 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      57. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:c37bb183-f272-4cae-96e1-7042c1dd7bcf (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      58. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:6701af43-bf7d-45c4-a331-a18d16bd68f7 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      59. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:fbb587fa-75c0-4f4d-8eaf-f0e7ba8b5c75 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      60. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:cbc8c074-f080-4489-a5ae-207b5fadeba3 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of WELLBUTRIN SR, peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      61. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:7d035056-44ab-444d-9d27-125b3f571140 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      62. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:c5d55b0c-8b81-476a-994e-1989e2a56255 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      63. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:a165869a-9bc4-4987-babe-a77fad78c38f (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (Cmax ) of bupropion is usually achieved within 3 hours.

      64. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:6563b923-269f-40c3-b992-cbacdfca6e16 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride and are approximately 10 times the peak level of the parent drug at steady state.

      65. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:f5d774dd-0f51-4a4f-a9d1-8b5f2364b1f7 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      66. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:8069c521-c49a-4b6d-baa8-4b0be897d585 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      67. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:29848192-7de3-4c0d-a822-1268dcf128b0 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      68. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:3c6b5ab4-9671-4fcd-8b4c-7f230dcfe6c9 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      69. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:4fbe64aa-f8f4-45fa-88ae-e844997703ae (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride and are approximately 10 times the peak level of the parent drug at steady state.

      70. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:1af890f7-1db8-4dd2-bf66-2b1e0c93a3d8 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      71. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:5604eb14-bab4-4f06-e063-6294a90a6920 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      72. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:39b2d509-1281-4464-9cf1-a94bbc18b84b (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release (SR) tablets, peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      73. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:d9bbacb3-63b4-2922-e053-2a95a90a6085 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      74. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:e2a988f2-f8d3-4de0-b9f1-49d8c2e4180f (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      75. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:3eec57be-b8ae-cdf8-e063-6394a90a694d (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      76. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:bd99969d-03d5-4609-88e8-a9ae93a83907 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      77. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:e962fb9a-d9fb-49c5-a8b4-0b355b8f829b (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      78. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:b59d950c-341f-45f1-b5b2-d64ccc799580 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      79. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:8d80f882-1887-4d73-b09f-e98fd7ef2acb (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      80. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:b0e10a21-0ae3-4a8b-bd3e-7a48b30f8418 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      81. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:4971c3cb-07c4-4c65-a16a-f1700e523147 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      82. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:9a3b97be-afa3-49e6-962f-662b6807e607 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride and are approximately 10 times the peak level of the parent drug at steady state.

      83. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:092da413-ec60-4577-ac57-51e3e42d55c9 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      84. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:9d0608a1-0cc8-491a-ad91-238e0ea009fe (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      85. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:6087100f-3ba4-412e-b08d-768d1dcdaf00 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      86. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:d1d1ed19-e111-4652-a0d4-9406e6f73e9f (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      87. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:f69b322b-93ab-407a-bf25-fe13c6896ca6 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      88. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:c76f2f9f-3999-4bdd-8ec3-e0066318d378 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      89. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:334e5635-e4cc-cf2a-e063-6294a90ae1e1 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      90. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:5038440c-1f32-715a-e063-6294a90a889d (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      91. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:1d722dc2-7909-454e-b989-095677079044 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      92. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:13770e60-117c-4814-93bb-9bc41a042a20 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (Cmax ) of bupropion is usually achieved within 3 hours.

      93. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:7d81ed30-ddf7-431a-84f8-6c630cf2b977 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      94. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:c1fa6fce-272b-4497-a958-177f0bafdfc7 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      95. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:f820ad7d-3c88-4a4f-e053-6294a90aef7b (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      96. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:38f52cec-9534-dab8-e063-6294a90a0704 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      97. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:90cc4f07-e0a3-4d50-a10a-8f6a7f9c5140 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      98. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:e4100232-a25d-4468-9057-af7e66205154 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      99. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:ec4d2256-0340-4166-90ee-c264eef3ac82 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      100. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:64934ca2-5655-45a2-9016-ad65b5abf5d3 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      101. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:620fab1e-aafb-444d-ab81-63281cd139c5 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      102. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:88c980c8-aaa8-4378-9ac2-24d588640caa (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      103. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:0865f8cf-1d7f-0e67-e063-6294a90a2f4d (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      104. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:5f8b3313-0286-499f-9235-02cdc0eb063b (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      105. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:d0eada89-e302-4ba3-bef0-e8c69af8206e (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      106. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:7c4313fa-bb29-dd50-e053-2991aa0a3005 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR) peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      107. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:2a13267f-c47f-4791-a8f9-4bbb5c804027 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      108. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:96d87edc-d12b-44b2-e053-2995a90a4e63 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In humans, following oral administration of Bupropion Hydrochloride Extended-release (SR) tablets, peak plasma concentration (Cmax) of bupropion is usually achieved within 3 hours.

      109. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:61e9cbe3-8211-42f3-b68f-581f56651919 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      110. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:b303a0ad-5971-44ab-937c-bcf3ff650358 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      111. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:e4c450ff-32bd-4359-8449-0b0d0b89a78c (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      112. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:f56ccdb1-f9d9-3e5f-e053-2995a90a8f16 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      113. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:4bd469b8-fb35-0223-e063-6294a90ae7bc (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      114. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:fd153957-ff74-4134-8545-cdc0e5619906 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      115. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:ad784c8e-7201-4336-a310-616e3e979ca4 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      116. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:4c9a5dc3-bebe-431a-b550-ce46c6c6b01e (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      117. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:867d3876-6974-4e89-bc45-9e60e84b401c (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      118. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:439a7e93-f578-434f-943f-4b93c35450f5 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In humans, following oral administration of bupropion hydrochloride extended-release (SR) tablets, peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      119. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:6948f63b-599c-4956-a249-e9544beda9fc (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      120. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:f8ad76a2-9f75-4660-973d-34402f314e9c (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR) peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      121. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:f566f8b5-b3c1-4234-88bd-59a7b8dc801a (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      122. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:35a873c5-4aa8-b3c7-e063-6394a90a35ec (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      123. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:0961f83e-25e9-4ffc-8669-44e4e9169978 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      124. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:b5c12c9a-62eb-481a-8099-7ad35242f7bf (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      125. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:9fb44e96-6160-4a4a-90cb-91764c0dcd89 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      126. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:5829a2aa-4845-b58b-e063-6294a90ad2f4 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      127. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:6dc4a55b-c0c0-4cbe-988e-da81f0c4f75e (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      128. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:7ded4fa6-e637-4d59-a1b1-286854d4fe3a (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In humans, following oral administration of bupropion hydrochloride extended-release (SR) tablets, peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      129. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:bb63261f-ad18-4885-9ed7-e7dfde33e171 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

      130. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:d1043c87-0abe-ee8e-e053-2a95a90a419a (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride tablets and are approximately 10 times the peak level of the parent drug at steady state.

      131. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:47b96919-a8ea-b769-e063-6394a90aa34e (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Following a single dose in humans, peak plasma concentrations of hydroxybupropion occur approximately 3 hours after administration of bupropion hydrochloride and are approximately 10 times the peak level of the parent drug at steady state.

      132. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:350336bf-57b1-4d2f-bf25-956bb6023c07 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           In humans, following oral administration of bupropion hydrochloride extended-release tablets (SR), peak plasma concentration (C max ) of bupropion is usually achieved within 3 hours.

   2. 5 hours

      Numeric value

      5

      Unit

      hours

      Source records

      119

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 119 source records

      1. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:d5469d64-5e74-4b7a-b4cd-551665f6adaa (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) tablets to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      2. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:459bd1c9-d7a5-8bc9-e063-6394a90a8ecd (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) tablets to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      3. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:722650d8-5ee4-48ba-9827-7c86b1283522 (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      4. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:b4a1d3b8-afcf-47e3-96d3-469d8f408a31 (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      5. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:c280efb9-b284-6a69-e053-2995a90a3035 (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      6. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:47ceb7e1-b2f7-47f8-8b6a-85eea36606b8 (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      7. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:9d08b4ae-077d-4cd8-9ca4-8d5cd63f400b (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      8. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:45789ff4-af5d-96b0-e063-6394a90a0644 (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      9. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:487271f1-c956-086a-e063-6394a90a2dc7 (opens source in a new tab)

         Bupropion label

         Version not recorded · Effective date not recorded

         Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      10. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:6902b252-dc69-4b3c-bad2-b6667a5f6d84 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      11. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:039d4368-c764-463a-b0cd-1cac702b8fb2 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      12. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:a5417808-f767-48fc-9f5d-c1aeee4e57c3 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) tablets to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      13. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:16a788ff-8bd5-4f70-a3fd-a89db019e435 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) tablets to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      14. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:98d5977f-9b32-46db-bd36-a2c4d1b0710a (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours under fasted conditions, and 12 hours under fed conditions.

      15. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:0cd6e0e2-6b2c-4e0d-b5b2-ebfe0d5e31c4 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      16. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:004d8121-59d4-46c4-acb8-b2dd097bf556 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      17. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:ae3bcdf7-d7f3-4f07-8113-af08af20a0d4 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      18. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:e4e38abf-ef67-405b-af2d-3d8e4533654d (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      19. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:ef8ef9ba-ab2a-4af9-ac11-12dd1b603a4a (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Ab sorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      20. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:5dec4414-5595-46c9-ada9-3fbe98152040 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      21. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:8dab6d17-bf41-4a28-90db-b66959c0e143 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      22. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:3ec04240-baef-44d7-8d73-a181171eec43 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrobromide extended-release tablets to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      23. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:cc344f7c-0eb3-4e63-a09e-b682acca2bb5 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      24. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:f53704b2-3d3c-47e8-9fd6-a0f5240c0593 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      25. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:7c46d95a-26f6-4364-8197-9e564e3405f2 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      26. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:15ad0c66-1829-59c3-e063-6394a90a4384 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      27. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:e57451fd-aba5-47d6-9892-ffe2a6021b6f (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion w as approximately 5 hours.

      28. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:64be3113-837a-48f3-9f9e-400529c9ee94 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Ab sorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      29. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:9d5360f5-f747-4baf-8e6c-ddca1a9c871a (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Ab sorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      30. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:fddc9630-2f9a-4104-888f-3714587d4fe7 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      31. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:d087222e-c5e9-4c48-b27f-e2e2944379c8 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      32. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:a435da9d-f6e8-4ddc-897d-8cd2bf777b21 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of Wellbutrin XL tablets to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      33. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:ed27c415-9f29-4789-9da4-4a14aaba95bd (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      34. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:4ddf6ba2-c020-7912-e063-6394a90a7964 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      35. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:af5b1cc8-f078-4a7b-b64a-4cb2de1e5721 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      36. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:5ccec958-998d-43a1-86fb-eb2b5e697b77 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      37. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:458c8a67-4995-c772-e063-6394a90a1f8d (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      38. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:eee88553-acff-4bdd-acd1-f39bcb6fcdca (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      39. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:d6efb695-c439-48d7-a155-5c661a5049af (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) tablets to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      40. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:0ac739de-ad59-4882-810e-f52db22ac96f (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) tablets to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      41. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:069e6828-e599-4614-9645-9cf1382ac93e (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      42. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:75b1e027-4c5d-46e5-98ee-033e67bd411c (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      43. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:c71f18b7-36a3-4489-96b4-e8fbec4f73a1 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      44. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:512b0ed3-db7d-b273-e063-6394a90a25cc (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      45. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:cefaaa17-f79a-4ba6-8f97-a59f60e07b75 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      46. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:56df4e22-81ca-48a4-a8e2-038448417355 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      47. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:f2b30440-0e07-2670-e053-2995a90afa28 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      48. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:34686e9d-c106-4276-8b47-7460cca8860e (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      49. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:a613cfd3-1aa1-49c5-b742-b105c97d73f1 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      50. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:29a6c6e3-f30f-6541-e063-6394a90ae11d (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      51. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:57a9f4d3-0c41-4978-b81e-cf3059bc8c42 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) tablets to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      52. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:0abd64f7-5142-48f6-a487-3f5bdc3400de (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      53. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:62d0dcb5-c70b-4884-9755-740f62a8b31a (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Ab sorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      54. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:2af578d8-a7f8-4da3-b126-390a0e950fad (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      55. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:4a2be6af-e256-4fa9-bfa9-5300d52cdaf4 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      56. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:80f4a4ef-8190-458d-af2e-5daaf32abc01 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      57. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:178c7129-a752-4ad9-ac82-4473e23bbacc (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) tablets to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      58. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:f8af7829-8b61-6785-e053-6294a90af052 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      59. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:2ccbf988-64b6-3a60-e063-6394a90ababa (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      60. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:16ffe2ac-4f71-4843-99df-611f53c2f3cd (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      61. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:f79d1422-a9b6-41c2-a46d-22886605f94d (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      62. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:740534d3-59b5-4938-8e38-16275a14438c (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      63. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:aa3d3e5b-74a3-47f6-b9aa-d6e248e950e5 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      64. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:d1d0872c-5b11-4e13-a401-b122348e0fa7 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      65. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:9e2d9c1e-a1de-491d-8f64-34ae60419611 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      66. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:637e89e5-8f6e-4392-8045-a778cb9ed138 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      67. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:4956af38-182a-4015-a945-67e40bd38772 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      68. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:42e228a2-25b3-44a6-8da7-6616ca44ac7f (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      69. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:e4f4d3fa-ddf6-4125-8486-8157efc095c1 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      70. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:a7553281-be90-47e3-8d2b-b027f6d18d3a (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      71. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:bf5e933c-8a84-4dd7-a05d-6c4a82b6c965 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      72. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:53c192ca-ac51-cb87-e063-6394a90a6c08 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      73. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:9aa3753f-1a0e-4faa-995f-67e29b320737 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      74. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:080853c0-fcab-4645-9ddc-4946e895ac5f (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      75. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:e47df78d-5e9b-485d-8d92-0e00602f7a31 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      76. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:a0fdfc21-165a-43fa-9b3c-e48f3b892250 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      77. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:c2cf79d7-1aba-4391-980b-5e218781f7c6 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Ab sorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      78. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:ec9cbb38-1582-492f-a526-4b3675c55b14 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      79. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:5d40e301-7e06-4ecd-b7c6-3d7ac6a134d2 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      80. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:8d937ca3-3351-40f1-8192-348ba0c68162 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      81. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:82bcdd72-9146-4c8d-a8aa-f92015864605 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      82. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:02275c51-6b3e-434a-bdb5-99135e73f1a4 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      83. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:4cc3327b-92c5-4667-ae16-3e95eafcf4d8 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      84. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:96e78f74-fad0-4ae1-9e68-55e4c6ab2d60 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) tablets to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      85. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:8a0781c0-e7d5-498e-b7d3-d6bd457f175f (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      86. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:8ae81b03-b447-4a3f-8ed9-ebf75ee52b49 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Ab sorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      87. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:42201f4a-8856-4499-8bc3-d18612b1ec34 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      88. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:5e568bb5-542a-4395-a21e-dc64281d694e (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) tablets to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      89. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:aeb506f8-97c2-409a-aac9-5a73c840e8f3 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      90. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:0e8b2109-8516-2d92-e063-6394a90a5d16 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      91. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:06d4d890-11ed-4f31-8778-c73432e3ea69 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      92. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:3d826804-6427-aae1-e063-6394a90a6593 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) tablets to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      93. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:eb25adb1-9841-42ce-aa22-718fb0fba5dd (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      94. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:8499470a-8d01-4348-b67b-8f49728031cb (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) tablets to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      95. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:b2e6c30f-a33c-4854-ab19-bc9f65880374 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      96. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:c60855ca-4fa0-4004-ad19-4abb61100c43 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      97. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:30c370c2-f2b7-4335-ba55-e8c8f4059092 (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      98. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:136f29fa-a859-4efb-8365-1382716d6f8f (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      99. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:1724f474-d6ab-46af-940f-7f874d4ff7fc (opens source in a new tab)

          Bupropion label

          Version not recorded · Effective date not recorded

          Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      100. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:15c4e95a-d203-4caf-b6c7-44792355cb76 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      101. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:05f82eca-cc87-4580-acd7-e6491c651881 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      102. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:6494d2d9-0ce4-4126-b1c7-49684395942b (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Absorption Following single oral administration of APLENZIN tablets to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      103. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:d9eb0939-63c1-48c4-a444-a899d7924d06 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      104. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:f1703bfd-be36-4fde-8e67-df0fb5d93369 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      105. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:df923448-4f81-47af-8e55-f7359746b05f (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      106. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:1af14d2e-c64d-44b7-a402-8869e8e30661 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      107. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:82872e51-3349-40fe-8ea3-496751955fed (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      108. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:a225dbbb-86f0-4547-a1c8-68eb64cd6892 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      109. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:dfd5f264-d4fd-4441-88b1-48086c7c0616 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      110. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:8d9779e7-300e-4720-8ba5-2272b2506cd9 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      111. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:77b78d35-40f5-4713-8468-aa09a6c2925d (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      112. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:a18b5460-fcbb-42dd-8b87-197d11a08928 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      113. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:2aabf040-16a6-b772-e063-6294a90afd70 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      114. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:2f9c5162-a6c5-e362-e063-6294a90a198d (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      115. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:80b01182-dc94-4990-8ebb-55c306d7e536 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Absorption Following single oral administration of FORFIVO XL tablets to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours under fasted conditions, and 12 hours under fed conditions.

      116. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:03b1b0a9-0aa2-4039-acce-68ca54abaae4 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) tablets to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      117. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:eb946d81-b4f4-42e9-aa7a-31d76d15629c (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      118. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:a1e768fd-c28f-4b49-822d-ccc315b4099c (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

      119. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:bcbef1b4-a135-4231-bc65-7d0b335260e8 (opens source in a new tab)

           Bupropion label

           Version not recorded · Effective date not recorded

           Absorption Following single oral administration of bupropion hydrochloride extended-release tablets (XL) to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.

3. Projected row 223

   Medicine slug

   buspirone

   Compared field

   proteinBinding

   Comparison state

   agree

   Reason codes

   • COMPATIBLE_VALUES_OVERLAP

   Documents examined

   169

   Source count

   169

   Agreement rate

   1

   Recorded readings

   1. 86%

      Numeric value

      86

      Unit

      %

      Source records

      169

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 169 source records

      1. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:05c006d2-44b9-431f-bce2-aff09c043ecb (opens source in a new tab)

         Buspirone label

         Version not recorded · Effective date not recorded

         An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      2. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:476f4f55-c6c1-4f39-950e-59236f499577 (opens source in a new tab)

         Buspirone label

         Version not recorded · Effective date not recorded

         An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      3. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:db32a7ec-5b50-4305-8952-df22e7e871e2 (opens source in a new tab)

         Buspirone label

         Version not recorded · Effective date not recorded

         An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      4. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:a6bdf140-075e-445e-a62d-633a4b97f3a8 (opens source in a new tab)

         Buspirone label

         Version not recorded · Effective date not recorded

         An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      5. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:0d46cf24-07e1-4bb7-8b5b-5ce12a030afd (opens source in a new tab)

         Buspirone label

         Version not recorded · Effective date not recorded

         An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      6. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:529ab1f9-534c-4a45-aa70-76e605247af1 (opens source in a new tab)

         Buspirone label

         Version not recorded · Effective date not recorded

         An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      7. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:f83219c9-8081-fe55-e053-6394a90aa924 (opens source in a new tab)

         Buspirone label

         Version not recorded · Effective date not recorded

         An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      8. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:63e2d4e2-f1ab-480d-b0bb-79b6cdb57a5d (opens source in a new tab)

         Buspirone label

         Version not recorded · Effective date not recorded

         An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      9. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:3da22999-f5fb-49fd-acde-c3006598e985 (opens source in a new tab)

         Buspirone label

         Version not recorded · Effective date not recorded

         An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      10. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:aba814f0-55ce-4480-99f1-b9ad1ba77d3f (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      11. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:18e90d65-4a3a-864e-e063-6294a90ae99d (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      12. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:e4d44e49-eb8f-454e-a737-22caf30bda78 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      13. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:1d883a13-4877-c6c7-e063-6294a90a5137 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      14. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:b42cc365-6259-4d2e-9648-d37718b65e1e (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      15. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:a9fc7091-b3ce-45fd-8d89-aeebdd81c327 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      16. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:fd05160d-24c6-4371-8b2c-c0f78c8b468e (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      17. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:cb0091ad-97f6-431b-b2b9-e03171eed274 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      18. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:2a8b3b75-5d93-4a9e-a583-49ccddd65650 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      19. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:69eb15e9-c33e-40a3-82d8-497dad13068d (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      20. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:fac49d42-7bc0-435f-bce2-2548dcdd6de6 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      21. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:d47cde56-e1ab-41fe-832e-d3f33b884a5e (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      22. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:37780596-3b6f-8d00-e063-6294a90ad4ad (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      23. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:ef8fc378-7fee-4d20-81ec-31211e34dc6e (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      24. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:40d5813d-d040-002c-e063-6294a90a5f7a (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      25. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:38677cd0-2ee6-4c8f-8553-36310b2813a1 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      26. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:eee7fa99-a9a1-4299-8a3d-6c2dd90948c9 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      27. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:fbff8248-b73c-474e-907e-449f8316c629 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      28. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:544b8918-7175-655f-e063-6394a90a453a (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      29. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:55810b17-4796-49d0-90e4-8e075d62eda4 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      30. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:7b222cb0-0061-4a3e-9d0f-e9f120e7f5d9 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      31. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:7db10b76-4520-496e-b450-66a662cc95f6 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      32. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:1521109d-8386-472f-9483-f1fe9f7ed152 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      33. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:75b1ae3f-e926-4555-a0e9-50323fc66cb2 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      34. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:2bc87b32-bdb7-4ce6-8a51-aed623f7219e (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      35. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:540e9b7e-09ff-2cca-e054-00144ff8d46c (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      36. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:fc0f93c8-2078-b2ff-e053-6294a90aacdf (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      37. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:ed2b56fe-e02f-46bc-808a-352f9bbb5b57 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      38. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:49659ee7-ca08-4df1-8e6b-3a366a7839c7 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      39. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:ff02c7cb-f96a-4a3b-99a2-812cd78b345c (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      40. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:427ad27e-6664-afee-e063-6394a90a1890 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      41. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:3f66a3fe-9d73-180c-e063-6394a90aacca (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      42. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:472049d2-c4d9-5a38-e063-6294a90a5cf1 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      43. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:72bff09c-826e-4394-a7e7-41d56ce9605b (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      44. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:3155e607-bc7f-4e90-9edf-8e862dd5737d (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      45. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:2acc7da1-d5b8-4404-a3c6-d51ed82cc4fd (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      46. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:8dc1ee33-e5aa-4462-8fb9-9bbdf5463488 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      47. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:97f2d082-0931-4e4f-a5be-7792e399e42b (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      48. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:459cc50d-0b18-ac1d-e063-6294a90ae7c4 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      49. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:91bb5fc9-5121-43c2-b2af-149240d4189a (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      50. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:da584ae1-4513-6474-e053-2a95a90aac9d (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      51. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:b7e3a98c-9ec5-4c21-9218-0d53a555a75c (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      52. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:7f6986a8-59dc-4dc3-bac0-b38cfc689f8f (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      53. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:62e4345a-2c51-4f93-89f0-282895ced785 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      54. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:501b0406-f56e-44d3-906a-7625b936f075 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      55. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:a8720833-3bbc-4714-b9b8-716c5e55410d (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      56. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:f8afd9b8-0885-2f0c-e053-6294a90a9c57 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      57. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:7ac98a7f-0ded-427f-899a-c3f6d1997403 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      58. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:897dac69-a59b-423c-be16-6301c7e504d9 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      59. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:1790d63d-ecb1-da9d-e063-6294a90a50ba (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      60. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:ed7e334a-cc4a-47b2-a4db-56495730b698 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      61. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:97fcebc1-6615-4b9d-b0f3-6434850f407c (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      62. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:4e7640d1-0a31-4f97-82bb-574cf1ff6e4a (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      63. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:8c811d3a-8b2d-44f5-bc8f-8eb563f18c3f (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      64. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:f318ba7b-121f-2e4f-e053-2a95a90a60c5 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      65. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:093b701d-4a43-4871-b726-c5820fa3ab95 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      66. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:66df7f74-5dea-46d6-9ef8-9bab37baf407 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      67. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:f101c5f3-d533-474d-a8bf-90d054933d16 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      68. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:ecdfd79e-7450-40ec-9561-cdda3a043990 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      69. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:f71e019b-3928-f8eb-e053-6394a90a871e (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      70. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:e8f43c66-f8de-419f-9ea9-43ddc4ec0798 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      71. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:24a95296-5fbe-49df-b1fe-4760d3a5ffe1 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      72. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:5fa0720f-e236-4b8b-a0c0-6f48037c76b3 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      73. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:2a25a718-306f-403e-9928-cae30bc52f12 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      74. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:55e32128-711d-4e95-b58b-e86e0afa4983 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      75. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:da6f4a74-a71e-4ccc-af2c-8de29e909c3b (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      76. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:20866697-58cd-4639-ae21-2fff486aec81 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      77. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:a738c103-134a-401f-b14c-49a599130b8d (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      78. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:3b41fd76-c3cc-77f0-e063-6294a90aa778 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      79. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:2df0b238-14a4-40ca-a235-411f6c9b8338 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      80. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:7c7225a0-8237-4998-843a-bf10fa6ec65b (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      81. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:bae98d45-e192-56e3-e053-2a95a90aadc3 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      82. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:ebda05ee-d895-4636-bc28-d393e69c91b3 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      83. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:53e7576a-e2f4-042b-e063-6294a90ae035 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      84. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:7c9eafb9-9ce1-4b28-900c-8fcb4b23424e (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      85. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:1315494d-7a51-4395-bc7c-afb4bc5482c9 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      86. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:d9de7cf1-c38d-8b3c-e053-2995a90aa26b (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      87. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:ad651fd5-fd91-4517-8de7-6fafd15ac7eb (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      88. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:bce96786-4d9a-460e-8d92-9908ea2af07a (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      89. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:6fac36b4-b223-479e-913f-f8c9cdb9e119 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      90. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:d5fcc60d-5465-4075-948c-1aa4ff21af4c (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      91. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:fbd7f3fa-11f8-a319-e053-6294a90acae4 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      92. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:f98d258d-6479-253a-e053-6394a90acbb3 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      93. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:187c315b-9c2c-485f-aa63-e399e0796e78 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      94. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:b9aa144c-cb36-4069-9eaa-7c150298cdd7 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      95. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:5b4da3f8-a5ce-4699-92e1-37fb95e0af2d (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      96. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:5424f933-93e1-4480-acdf-bd8667ae50e9 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      97. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:a2867dde-e5dd-4cc8-84d0-59240626868a (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      98. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:1886b672-4b88-4b49-ae6a-d2ba2f452e44 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      99. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:27db85e9-68ef-4d43-a319-4e2ec8dbae05 (opens source in a new tab)

          Buspirone label

          Version not recorded · Effective date not recorded

          An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      100. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:fbab1056-b63e-473e-9259-ba099d884d2b (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      101. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:96789fdc-f3a0-4441-b9f4-2be2d9c6273b (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      102. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:38faa7cb-d858-4481-8649-35d228acbd38 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      103. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:b6352207-e708-44a7-8a63-93b96613e1e7 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      104. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:bee0edbf-3fc3-484b-9715-f13a329216ae (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      105. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:07a789a9-c9e8-4737-a56d-7d5405fe8100 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      106. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:510120d3-c922-a071-e063-6294a90af6a7 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      107. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:fa3f9c0e-261d-4ceb-8cc7-e5e013563479 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      108. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:544a4570-bd7f-72bb-e063-6394a90ab8d6 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      109. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:5718bc19-07b2-b61d-e063-6394a90a6e80 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      110. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:cff9f09a-1ea2-4968-b57b-e62bebaae238 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      111. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:cff1c7b2-4edb-4b5a-9626-2f7b8671b015 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      112. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:19afb386-72a5-c97e-e063-6294a90adaea (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      113. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:8b6e7ae6-5b83-4a5a-ab45-cf4be4287d78 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      114. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:267d8897-90dd-4f8a-bbd8-8aa4e47c2905 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      115. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:b07c0a91-892c-47f5-819e-a128e0ef1ed7 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      116. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:b08dd2e7-e808-4b51-b404-5009076b82eb (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      117. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:14fd7c1c-778e-46d4-9024-89b319f15f39 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      118. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:08efb26e-488c-49d4-8432-98db855962e9 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      119. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:fa4d5cac-f687-4440-99d2-8bb27cf2f4ed (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      120. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:65c69118-36bb-4f0d-9669-b52556056ec5 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      121. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:3dd7f213-afd8-67d6-e063-6294a90ac108 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      122. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:438f5c4d-a009-b851-e063-6394a90a084a (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      123. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:18ddef0b-1451-4bea-94fb-b6ec27f4744b (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      124. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:b230197c-3d50-7874-e053-2a95a90af50f (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      125. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:824c80e6-d508-405f-8a4f-2f10df5a9dc8 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      126. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:02628a0c-bfdb-4a58-8e48-bcd8ca12d53b (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      127. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:bcce49d3-c8eb-9f9b-e053-2995a90a67d9 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      128. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:138b84a5-966b-47d7-a3d6-395df83f8aa5 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      129. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:45c637b7-3057-ea38-e063-6394a90a87b6 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      130. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:338f3317-96c0-4b8a-8299-8ce2a10911ae (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      131. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:3246dd4d-f787-2f62-e063-6294a90a9cd2 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      132. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:864ddd0c-80e5-4b4b-84e9-7d66214464ae (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      133. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:9a702362-39cb-4171-8d64-f37fa7e1f638 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      134. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:03efd618-8ca3-43d0-bbeb-55e53b5308e8 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      135. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:eab53fff-c052-4466-a673-3d68aab98c27 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      136. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:3c115eea-9dbc-4e2c-9d79-42e3388fde5a (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      137. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:696911d8-e97a-4c8e-9341-782b4c63bf03 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      138. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:932422a8-b72c-4dab-b942-2ab092ed6b01 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      139. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:30c93022-4126-db8c-e063-6394a90a7579 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      140. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:335107c9-5799-c4df-e063-6294a90a5ca0 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      141. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:5d93a30e-3544-44e7-ab6a-dc9dc79d7c71 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      142. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:f85b59b7-b945-4440-8378-987bd287a655 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      143. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:270398a0-21b8-407b-af76-4aeef90f72be (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      144. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:4ff72575-bd60-40ce-b3a8-fd92b79af674 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      145. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:eb072818-3ca8-430b-91a1-e7fedd37990c (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      146. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:424d81f0-b195-5bc2-e063-6394a90a2104 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      147. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:8e9c0553-c994-f54a-e053-2a95a90a6fa3 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      148. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:4d1ae09a-3ead-4604-8d13-590f41f63b96 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      149. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:8e0219e9-d305-4473-8229-aee0ee84caf6 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      150. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:84621631-4c13-4147-ae3c-4ed30d4ebb37 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      151. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:068ee1a0-a77a-4803-bad9-18117d7fb358 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      152. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:6c6db7a9-a728-406a-81af-edd89e1cc26f (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      153. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:50b18368-d37c-374b-e063-6394a90a8114 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      154. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:801803eb-be17-4064-8813-7ccf52316cde (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      155. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:4adc1750-b89e-473d-a18f-949423a2354f (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      156. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:310c6bea-838b-43e4-87e0-a0050829c242 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      157. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:e2c672b3-6130-4dd1-8066-0ce9451cb8c7 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      158. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:efa03f52-430e-455a-bdca-7f9d422b7b19 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      159. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:fa8171d4-f73c-4a91-973d-cb46c5507081 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      160. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:4ae45cb1-8612-4006-b12c-2440160132ac (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      161. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:e80d83a6-7c2a-478e-bdf1-c481824fc301 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      162. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:8bb7991e-ab09-4602-b49d-0a72a501685b (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      163. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:48b4e52d-d4c4-4d24-a0ac-24316371cef0 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      164. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:b217f341-7d51-475d-887f-f16786164c7b (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      165. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:790b6159-c03b-4a3a-be6b-add35a3114a4 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      166. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:160f52d2-2e08-4969-80c3-c653767652f0 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      167. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:225575f1-9635-4922-8286-d479d6480bf0 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      168. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:2c516eec-65d9-4481-8823-ae6b6da84062 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

      169. FDA_LABEL·Retrieved 2026-08-30

           FDA_LABEL:a9bb9216-3dac-4e8a-9df9-f72c2eaef160 (opens source in a new tab)

           Buspirone label

           Version not recorded · Effective date not recorded

           An in vitro protein binding study indicated that approximately 86% of buspirone is bound to plasma proteins.

4. Projected row 224

   Medicine slug

   butorphanol

   Compared field

   bioavailability

   Comparison state

   insufficient_context

   Reason codes

   • STRUCTURED_CONTEXT_MISSING

   Documents examined

   5

   Source count

   5

   Agreement rate

   0.6

   Recorded readings

   1. 60 to 70%

      Numeric value

      60

      Unit

      %

      Source records

      3

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 3 source records

      1. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:5a50d22e-acbe-4b15-9ed6-70713378408a (opens source in a new tab)

         Butorphanol label

         Version not recorded · Effective date not recorded

         The absolute bioavailability of Butorphanol Tartrate Nasal Spray is 60 to 70% and is unchanged in patients with allergic rhinitis.

      2. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:b8e48063-0b40-ee43-85c1-4ef2de80c404 (opens source in a new tab)

         Butorphanol label

         Version not recorded · Effective date not recorded

         The absolute bioavailability of butorphanol tartrate nasal spray is 60 to 70% and is unchanged in patients with allergic rhinitis.

      3. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:412499ce-db93-4943-ae1a-564c27b1fb16 (opens source in a new tab)

         Butorphanol label

         Version not recorded · Effective date not recorded

         The absolute bioavailability of butorphanol tartrate nasal spray is 60 to 70% and is unchanged in patients with allergic rhinitis.

   2. 5 to 17%

      Numeric value

      5

      Unit

      %

      Source records

      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records

      1. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:bded5531-8847-4576-9a29-3e44f979d2e0 (opens source in a new tab)

         Butorphanol label

         Version not recorded · Effective date not recorded

         Oral bioavailability is only 5 to 17% because of extensive first pass metabolism of butorphanol.

      2. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:9822ca3f-aee2-46e5-8a96-495400e65d10 (opens source in a new tab)

         Butorphanol label

         Version not recorded · Effective date not recorded

         Oral bioavailability is only 5 to 17% because of extensive first pass metabolism of butorphanol.

5. Projected row 225

   Medicine slug

   butorphanol

   Compared field

   halfLife

   Comparison state

   agree

   Reason codes

   • COMPATIBLE_VALUES_OVERLAP

   Documents examined

   5

   Source count

   5

   Agreement rate

   1

   Recorded readings

   1. 18 hours

      Numeric value

      18

      Unit

      hours

      Source records

      5

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 5 source records

      1. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:5a50d22e-acbe-4b15-9ed6-70713378408a (opens source in a new tab)

         Butorphanol label

         Version not recorded · Effective date not recorded

         The elimination half-life of hydroxybutorphanol is about 18 hours and, as a consequence, considerable accumulation (~5-fold) occurs when butorphanol is dosed to steady state (1 mg transnasally q6h for 5 days).

      2. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:bded5531-8847-4576-9a29-3e44f979d2e0 (opens source in a new tab)

         Butorphanol label

         Version not recorded · Effective date not recorded

         The elimination half-life of hydroxybutorphanol is about 18 hours and, as a consequence, considerable accumulation (<5-fold) occurs when butorphanol is dosed to steady state.

      3. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:b8e48063-0b40-ee43-85c1-4ef2de80c404 (opens source in a new tab)

         Butorphanol label

         Version not recorded · Effective date not recorded

         The elimination half-life of hydroxybutorphanol is about 18 hours and, as a consequence, considerable accumulation (~5-fold) occurs when butorphanol is dosed to steady state (1 mg transnasally q6h for 5 days).

      4. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:412499ce-db93-4943-ae1a-564c27b1fb16 (opens source in a new tab)

         Butorphanol label

         Version not recorded · Effective date not recorded

         The elimination half-life of hydroxybutorphanol is about 18 hours and, as a consequence, considerable accumulation (~5-fold) occurs when butorphanol is dosed to steady state (1 mg transnasally q6h for 5 days).

      5. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:9822ca3f-aee2-46e5-8a96-495400e65d10 (opens source in a new tab)

         Butorphanol label

         Version not recorded · Effective date not recorded

         The elimination half-life of hydroxybutorphanol is about 18 hours and, as a consequence, considerable accumulation (~5-fold) occurs when butorphanol is dosed to steady state.

6. Projected row 226

   Medicine slug

   butorphanol

   Compared field

   volumeOfDistribution

   Comparison state

   agree

   Reason codes

   • COMPATIBLE_VALUES_OVERLAP

   Documents examined

   5

   Source count

   5

   Agreement rate

   1

   Recorded readings

   1. 305 to 901 liters

      Numeric value

      305

      Unit

      L

      Source records

      5

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 5 source records

      1. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:5a50d22e-acbe-4b15-9ed6-70713378408a (opens source in a new tab)

         Butorphanol label

         Version not recorded · Effective date not recorded

         The volume of distribution of butorphanol varies from 305 to 901 liters and total body clearance from 52 to 154 liters/hr (see Table 1 ).

      2. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:bded5531-8847-4576-9a29-3e44f979d2e0 (opens source in a new tab)

         Butorphanol label

         Version not recorded · Effective date not recorded

         The volume of distribution of butorphanol varies from 305 to 901 liters and total body clearance from 52 to 154 liters/hr (see Table 1).

      3. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:b8e48063-0b40-ee43-85c1-4ef2de80c404 (opens source in a new tab)

         Butorphanol label

         Version not recorded · Effective date not recorded

         The volume of distribution of butorphanol varies from 305 to 901 liters and total body clearance from 52 to 154 liters/hr (see Table 1 ).

      4. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:412499ce-db93-4943-ae1a-564c27b1fb16 (opens source in a new tab)

         Butorphanol label

         Version not recorded · Effective date not recorded

         The volume of distribution of butorphanol varies from 305 to 901 liters and total body clearance from 52 to 154 liters/hr (see Table 1 ).

      5. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:9822ca3f-aee2-46e5-8a96-495400e65d10 (opens source in a new tab)

         Butorphanol label

         Version not recorded · Effective date not recorded

         The volume of distribution of butorphanol varies from 305 to 901 liters and total body clearance from 52 to 154 liters/hr (see Table 1 ).

7. Projected row 227

   Medicine slug

   cabergoline

   Compared field

   halfLife

   Comparison state

   agree

   Reason codes

   • COMPATIBLE_VALUES_OVERLAP

   Documents examined

   13

   Source count

   8

   Agreement rate

   1

   Recorded readings

   1. 60 hours

      Numeric value

      60

      Unit

      hours

      Source records

      8

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 8 source records

      1. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:275a6a25-c3c9-4258-a610-0b00752517f7 (opens source in a new tab)

         Cabergoline label

         Version not recorded · Effective date not recorded

         Radioactivity in the pituitary exceeded that in plasma by >100-fold and was eliminated with a half-life of approximately 60 hours.

      2. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:89ec147b-a6fe-49bb-9af5-52fc2ce5db7f (opens source in a new tab)

         Cabergoline label

         Version not recorded · Effective date not recorded

         Radioactivity in the pituitary exceeded that in plasma by >100-fold and was eliminated with a half-life of approximately 60 hours.

      3. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:9405c116-4a77-4e14-9ab8-25e899595cdf (opens source in a new tab)

         Cabergoline label

         Version not recorded · Effective date not recorded

         Radioactivity in the pituitary exceeded that in plasma by > 100‑fold and was eliminated with a half-life of approximately 60 hours.

      4. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:518d43ee-8d33-4abd-96a5-1b6890e59b08 (opens source in a new tab)

         Cabergoline label

         Version not recorded · Effective date not recorded

         Radioactivity in the pituitary exceeded that in plasma by >100-fold and was eliminated with a half-life of approximately 60 hours.

      5. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:e0fb5556-de2c-4822-9960-0700e2907890 (opens source in a new tab)

         Cabergoline label

         Version not recorded · Effective date not recorded

         Radioactivity in the pituitary exceeded that in plasma by >100-fold and was eliminated with a half-life of approximately 60 hours.

      6. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:7699d938-3f62-4e13-9b33-3e581310b9f3 (opens source in a new tab)

         Cabergoline label

         Version not recorded · Effective date not recorded

         Radioactivity in the pituitary exceeded that in plasma by >100-fold and was eliminated with a half-life of approximately 60 hours.

      7. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:a246b015-e19c-4b4f-9089-aea1108687ba (opens source in a new tab)

         Cabergoline label

         Version not recorded · Effective date not recorded

         Radioactivity in the pituitary exceeded that in plasma by > 100‑fold and was eliminated with a half-life of approximately 60 hours.

      8. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:bc44d11b-b3f0-4e3d-9da3-4f8852d11734 (opens source in a new tab)

         Cabergoline label

         Version not recorded · Effective date not recorded

         Radioactivity in the pituitary exceeded that in plasma by >100-fold and was eliminated with a half-life of approximately 60 hours.

8. Projected row 228

   Medicine slug

   cabergoline

   Compared field

   proteinBinding

   Comparison state

   agree

   Reason codes

   • COMPATIBLE_VALUES_OVERLAP

   Documents examined

   13

   Source count

   5

   Agreement rate

   1

   Recorded readings

   1. 40%

      Numeric value

      40

      Unit

      %

      Source records

      5

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 5 source records

      1. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:8562f94f-a59a-4893-aefc-ea6547b01e92 (opens source in a new tab)

         Cabergoline label

         Version not recorded · Effective date not recorded

         Distribution Protein binding of cabergoline was 40% to 42%.

      2. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:74b61e8a-7ae9-4996-85ec-df23c56de16f (opens source in a new tab)

         Cabergoline label

         Version not recorded · Effective date not recorded

         Distribution Protein binding of cabergoline was 40% to 42%.

      3. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:c9f0b576-d5e5-4e3e-bb5c-3574d75d9907 (opens source in a new tab)

         Cabergoline label

         Version not recorded · Effective date not recorded

         Distribution Protein binding of cabergoline was 40% to 42%.

      4. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:57cbd81e-fdb9-4060-80ee-6e8581c463a4 (opens source in a new tab)

         Cabergoline label

         Version not recorded · Effective date not recorded

         Distribution Protein binding of cabergoline was 40% to 42%.

      5. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:e497366b-a124-4d7f-bd45-a883c392d4bb (opens source in a new tab)

         Cabergoline label

         Version not recorded · Effective date not recorded

         Distribution Protein binding of cabergoline was 40% to 42%.

9. Projected row 229

   Medicine slug

   cabozantinib

   Compared field

   halfLife

   Comparison state

   insufficient_context

   Reason codes

   • STRUCTURED_CONTEXT_MISSING

   Documents examined

   2

   Source count

   2

   Agreement rate

   0.5

   Recorded readings

   1. 55 hours

      Numeric value

      55

      Unit

      hours

      Source records

      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records

      1. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:1a0c3bea-c87b-4d25-bb44-5f0174da6b34 (opens source in a new tab)

         Cabozantinib label

         Version not recorded · Effective date not recorded

         Elimination The predicted effective half-life is approximately 55 hours and the clearance (CL/F) at steady-state is estimated to be 4.4 L/hr.

   2. 99 hours

      Numeric value

      99

      Unit

      hours

      Source records

      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records

      1. FDA_LABEL·Retrieved 2026-08-30

         FDA_LABEL:3850cce2-6137-42e5-a792-d318c4a4b3b5 (opens source in a new tab)

         Cabozantinib label

         Version not recorded · Effective date not recorded

         Elimination The predicted terminal half-life is approximately 99 hours and the clearance (CL/F) at steady-state is estimated to be 2.2 L/hr.

10. Projected row 230

    Medicine slug

    cabozantinib

    Compared field

    volumeOfDistribution

    Comparison state

    insufficient_context

    Reason codes

    • STRUCTURED_CONTEXT_MISSING

    Documents examined

    2

    Source count

    2

    Agreement rate

    0.5

    Recorded readings

    1. 319 L

       Numeric value

       319

       Unit

       L

       Source records

       1

       Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

       Show all 1 source records

       1. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:3850cce2-6137-42e5-a792-d318c4a4b3b5 (opens source in a new tab)

          Cabozantinib label

          Version not recorded · Effective date not recorded

          Distribution The oral volume of distribution (V z /F) of cabozantinib is approximately 319 L.

    2. 349 L

       Numeric value

       349

       Unit

       L

       Source records

       1

       Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

       Show all 1 source records

       1. FDA_LABEL·Retrieved 2026-08-30

          FDA_LABEL:1a0c3bea-c87b-4d25-bb44-5f0174da6b34 (opens source in a new tab)

          Cabozantinib label

          Version not recorded · Effective date not recorded

          Distribution The oral volume of distribution (V/F) of cabozantinib is approximately 349 L.